97 related articles for article (PubMed ID: 10676654)
1. Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors.
Willimsky G; Blankenstein T
Cancer Res; 2000 Feb; 60(3):685-92. PubMed ID: 10676654
[TBL] [Abstract][Full Text] [Related]
2. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation.
Cayeux S; Richter G; Noffz G; Dörken B; Blankenstein T
J Immunol; 1997 Mar; 158(6):2834-41. PubMed ID: 9058819
[TBL] [Abstract][Full Text] [Related]
3. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
Xiang J; Chen Y; Moyana T
Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
[TBL] [Abstract][Full Text] [Related]
4. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines.
Hull GW; Mccurdy MA; Nasu Y; Bangma CH; Yang G; Shimura S; Lee HM; Wang J; Albani J; Ebara S; Sato T; Timme TL; Thompson TC
Clin Cancer Res; 2000 Oct; 6(10):4101-9. PubMed ID: 11051263
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy.
Lohr F; Hu K; Haroon Z; Samulski TV; Huang Q; Beaty J; Dewhirst MW; Li CY
Mol Ther; 2000 Sep; 2(3):195-203. PubMed ID: 10985949
[TBL] [Abstract][Full Text] [Related]
7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic antitumor response to cervical cancer in mice immunized with U14 vaccines transfected with costimulatory B7 gene.
Tao G; Hu J; Zou H; Lin Q; Liu F; Wu Y; Sun Q
Chin Med J (Engl); 2001 Jun; 114(6):623-7. PubMed ID: 11780440
[TBL] [Abstract][Full Text] [Related]
9. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
10. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
11. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
Chen PW; Ksander BR
Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth.
Campbell I; Moyana T; Carlsen S; Zheng C; Xiang J
Cancer Gene Ther; 2000 Jan; 7(1):37-44. PubMed ID: 10678354
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated in vivo B7-1 gene transfer induces anti-tumor immunity against pre-established primary tumor and pulmonary metastasis of rat osteosarcoma.
Tsuji H; Kawaguchi S; Wada T; Nagoya S; Inobe M; Yamashita T; Ishii S; Uede T
Cancer Gene Ther; 2002 Sep; 9(9):747-55. PubMed ID: 12189524
[TBL] [Abstract][Full Text] [Related]
14. Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect.
Liu X; Zhang L; Zhang M; Ma Y; Xu X; Cai Y
Chin Med J (Engl); 2000 Feb; 113(2):167-71. PubMed ID: 11775545
[TBL] [Abstract][Full Text] [Related]
15. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy.
Tatsumi T; Gambotto A; Robbins PD; Storkus WJ
Cancer Res; 2002 Oct; 62(20):5853-8. PubMed ID: 12384548
[TBL] [Abstract][Full Text] [Related]
17. Decreased generation of anti-tumor immunity after intrasplenic immunization.
Cayeux S; Qin Z; Dörken B; Blankenstein T
Eur J Immunol; 2001 May; 31(5):1392-9. PubMed ID: 11465096
[TBL] [Abstract][Full Text] [Related]
18. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
Kim TS; Lee BC; Kim E; Cho D; Cohen EP
Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
[TBL] [Abstract][Full Text] [Related]
19. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]